2 citations
,
March 2023 in “Frontiers in medicine” A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
2 citations
,
April 2025 in “Biologics” Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
Intralesional methotrexate effectively treats alopecia areata by reducing TNF-α levels, leading to hair regrowth.
22 citations
,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
May 2023 in “Elsevier eBooks” Stem cell-based therapies show promise for treating various medical conditions.
184 citations
,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
5 citations
,
August 2018 in “PubMed” An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.
114 citations
,
October 2006 in “Journal of the European Academy of Dermatology and Venereology” The new clobetasol propionate foam is effective and safe for treating alopecia areata.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
December 2017 in “Annales de dermatologie et de vénéréologie” In 2017, pediatric dermatology advanced with new treatments and insights into various skin conditions in children.
9 citations
,
August 2002 in “Current Opinion in Pediatrics” An 18-year-old girl with pemphigus vulgaris needed strong medication and careful treatment due to ineffective initial therapies and side effects.
3 citations
,
October 2018 in “Journal of Mind and Medical Sciences” Biological therapy boosts the immune system to effectively fight melanoma.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
October 2024 in “BMJ Case Reports” Baricitinib effectively treats both rheumatoid arthritis and alopecia areata.
January 2023 in “Journal of cosmetic dermatology” The synthetic retinoid EC23 thickens skin and promotes hair growth more effectively and with a lower dose than natural retinoids.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
16 citations
,
March 1996 in “PubMed” Switching to twice-weekly betamethasone led to full hair regrowth in 3 months without side effects.
1 citations
,
March 2024 in “BioDrugs” Biologics for severe asthma have known side effects, but some new risks need more study.
November 2025 in “Journal of Investigative Dermatology” TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
The FDA did not approve a testosterone drug because of safety concerns.
December 2022 in “IntechOpen eBooks” 308 excimer phototherapy is a safe and effective way to treat hair loss from Alopecia Areata.
March 2026 in “International Journal of Pharmaceutics and Drug Analysis” The polyherbal emulgel is a promising treatment for rheumatoid arthritis with effective and sustained results.
September 2024 in “Cureus” Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.